46 results about "Pharmasolve" patented technology

There is provided a film coated pharmaceutical composition comprising 5 '-deoxy-5-fluoro-N-[(pentyloxy)-carbonyl]-cytidine (capecitabine) and at least one disintegrant selected from the group comprising of crospovidone (particle size < 15-400 [mu]), croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropylcellulose, Ludiflash TM or any combination of these, together with other pharmaceutically acceptable excipients to form a rapidly disintegrating tablet.

A eutectic-based self-nanoemulsified drug delivery system (SNEDDS) is formulated from polyoxyl 35 castor oil (Cremophor), medium chain mono- and diglycerides (capmul), essential oils, and a pharmacologically effective drug. The preferred pharmacologically effective drug is a poorly water soluble drug, such as ubiquinone (CoQ10). The SNEDDS can be further incorporated into a powder to produce a solid dosage form. The solid dosage form contains the SNEDDS, a copolymer of vinylpyrrolidone and vinyl acetate (Kollidon VA 64), maltodextrin, and microcrystalline cellulose (MCC).

Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excipient support material, a polyvinylpyrrolidone or crospovidone, croscarmellose sodium, granular mannitol, sodium dodecyl sulfate, silicon dioxide, and a stearate, wherein the fenofibrate is in the form of microparticles, and wherein at least a portion of the phospholipid is coated on the surfaces of the fenofibrate microparticles, the phospholipid coated microparticles are embedded in a matrix comprising the water-soluble bulking agent, phospholipid that is not coated on the microparticles, the buffer salt and the cellulosic additive, and the matrix is coated on up to 100% of the surfaces of the beads or crystals of the excipient support material.

The invention provides orally disintegrating tablets for treating functional dyspepsia, and the orally disintegrating tablets are prepared from gold thread extract, magnolia bark extract, acorus gramineus extract, processed pinellia tuber extract, baical skullcap root extract, dried tangerine peel extract, reed rhizome extract, oriental wormwood extract, raw coix extract, crosslinked polyvinylpyrrolidone used as a disintegrating agent, microcrystalline cellulose used as filler, magnesium stearate used as a lubricant and aspartame used as a flavoring agent. Patients suffering from spleen-stomach damp-heat syndrome functional dyspepsia are divided into a test group and a control group by adopting a multi-center random double-blind placebo control method, and 4 weeks are taken as a course of treatment. Results indicate that: the orally disintegrating tablets have excellent clinical curative effect to the functional dyspepsia spleen-stomach damp-heat syndrome, overcome the defects of the conventional Chinese medicinal preparation for treating the functional dyspepsia, and have safety and efficiency, low cost and convenient control.

The invention relates to a preparation method of linezolid injection, which belongs to the field of pharmaceutical preparations. The preparation method of the linezolid injection comprises: adding 400mL of water for injection, adding 2.3g of sodium acetate trihydrate and 1.2g of sodium chloride in sequence, placing it at a temperature of 0-5°C for 18-36 hours, and then Add 1.62g of sodium citrate and 0.85g-1.2g of citric acid in sequence, then add 50g of glucose, stir until completely dissolved to obtain a medicinal solution, add activated carbon, stir and absorb at 60-70°C for 15-25 minutes, then decarbonize to obtain The first filtrate; add 2g linezolid, 0.01g sodium bisulfite and 0.03g aluminum chloride to the first filtrate, stir and mix at 80-90℃, then add 50mL N-methylpyrrolidone, 10mL dimethyl sulfoxide and Add water for injection to 1000mL, stir to make the liquid medicine uniform, adjust the pH value of the liquid medicine to 4.4-5.0, filter to obtain the second filtrate; fill the second filtrate to obtain the linezolid injection. The quality of the linezolid injection prepared by the method is stable, and the pyrogen is qualified.

A pharmaceutical composition, an osmotic pump controlled-release drug delivery system containing the pharmaceutical composition and a preparation method thereof. The pharmaceutical composition comprises a tablet core and a coating film, the tablet core comprises a drug pulling layer, the coating film comprises 50-90% by weight of cellulose acetate and 10-50% by weight of copovidone, and the copolyvidone Ketones are prepared by polymerizing vinylpyrrolidone and vinyl acetate in a molar ratio of 40:60‑80:20.

The present invention relates to a moisturizing facial mask. The composite moisturizing agent is added to the facial mask of the present invention, and its composition and dosage are (wt%): sodium hyaluronate 0.01-5.0, wrinkled carrageenan 0.01-5.0, sodium polyglutamate 0.01-5.0, glycerin 0.001-40.0 , L-serine 0.01-2.0, L-proline 0.00-2.0, L-glutamic acid 0.0-0.3, betaine 0.001-15.0, urea 0.0-20.0, sodium pyrrolidone carboxylate 0.001-15.0, trehalose 0.0-10.0 , preservative 0.0‑1.0, allantoin 0.001‑0.5, pH regulator 0.001‑5.0. The moisturizing facial mask of the invention has film-forming properties, can exert a lasting and efficient moisturizing effect, and has wide application prospects.